Silk Road Medical(US:SILK)2024-08-07 20:07Financial Performance - Revenue for Q2 2024 was $51.2 million, an increase of $5.9 million or 13% compared to Q2 2023[1] - Gross profit for Q2 2024 was $38.5 million, with a gross margin of 75%, up from 71% in Q2 2023[2] - Operating expenses increased by 20% to $55.7 million in Q2 2024, compared to $46.6 million in the same period last year[2] - Net loss for Q2 2024 was $16.6 million, or $0.42 per share, compared to a loss of $13.5 million, or $0.35 per share, in Q2 2023[2] - Adjusted EBITDA loss improved to $1.1 million in Q2 2024 from a loss of $3.4 million in Q2 2023[2] Cash and Assets - Cash, cash equivalents, and investments totaled $186.2 million as of June 30, 2024[2] - Total assets as of June 30, 2024, were $269.8 million, up from $265.3 million at the end of 2023[9] - The accumulated deficit increased to $430.2 million as of June 30, 2024, from $399.5 million at the end of 2023[9] Research and Development - Research and development expenses for Q2 2024 were $11.9 million, compared to $10.8 million in Q2 2023[8] Guidance and Acquisitions - The company has withdrawn its full year 2024 financial guidance due to the proposed acquisition by Boston Scientific[3]